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Abstract
Background: Severe limb ischaemia (SLI) is defined as the presence of rest pain and/or tissue loss secondary to
lower extremity atherosclerotic peripheral arterial disease. The superficial femoral and popliteal arteries are the most
commonly diseased vessels in such patients and are being increasingly treated using endovascular revascularisation
techniques. However, it is currently unknown whether drug-eluting stents and drug-coated balloons confer
additional clinical benefits over more established techniques using plain balloons and bare metal stents, or whether
they represent a cost-effective use of NHS resources.
Methods: The BASIL-3 trial is a UK National Institute for Health Research, Health Technology Assessment
Programme-funded, multicentre, randomised controlled trial (RCT) comparing the clinical and cost-effectiveness of
plain balloon angioplasty with or without bail-out bare metal stenting, drug-coated balloon angioplasty with or
without bail-out bare metal stenting, and primary stenting with drug-eluting stents for SLI secondary to femoro-
popliteal disease. Patients with ‘multilevel’ disease may receive aorto-iliac and/or infrapopliteal treatments
concurrently with their randomised femoro-popliteal intervention. The primary clinical outcome is amputation-free
survival defined as the time to major (above the ankle) amputation of the index limb or death from any cause. The
primary outcome for the economic analysis is cost per quality-adjusted life year. Secondary outcome measures
include overall survival, major adverse limb events, major adverse cardiac events, relief of ischaemic pain, healing of
tissue loss, and quality of life. The required sample size has been calculated at 861 participants (287 on each arm).
These patients will be recruited over 3 years and followed-up for between 2 and 5 years.
Discussion: BASIL-3 is a pragmatic RCT designed to reflect current UK clinical practice. The results will inform
decision-making regarding the appropriateness of funding the use of drug-coated balloons and drug-eluting stents,
by the NHS, for the management of SLI due to femoro-popliteal disease.
Trial registration: ISRCTN Registry, identifier: ISRCTN14469736. Registered on 22 October 2015.
Keywords: Severe limb ischaemia, Critical limb ischaemia, Endovascular treatment, Angioplasty, Stent, Drug-coated
balloon, Drug-eluting stent, Diabetes, Cost-effectiveness
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Background
Peripheral arterial disease (PAD) is caused by a gradual
build-up of atheroma within the arterial wall leading to
the lumen becoming stenosed (narrowed) and ultim-
ately occluded. Modifiable risk factors for the develop-
ment of PAD include cigarette smoking, hypertension,
dyslipidaemia, diabetes mellitus (DM), chronic kidney
disease (CKD), increased Body Mass Index, and seden-
tary lifestyle. PAD is also associated with increasing
age and male sex, and there may be a familial predis-
position in some cases [1]. PAD presents as a con-
tinuum from asymptomatic disease to intermittent
claudication (pain in the leg on walking due to ischae-
mia, relieved by rest) through to severe (or critical)
limb ischaemia (SLI) characterised by [2]:
1. Severe and constant ischaemic pain which is
experienced at rest, especially at night, usually in
the forefoot
2. Tissue loss in the form of ulceration or gangrene,
typically this starts with a minor foot injury which
fails to heal and/or becomes infected
In the Western world, it has been estimated that there
will be between 500 and 1000 new cases of SLI each year
per million general population although the current
epidemiology of SLI in the United Kingdom (UK) is not
well defined [3]. The incidence of SLI is increasing
globally as a consequence of ageing populations and the
increasing prevalence of modifiable risk factors, espe-
cially tobacco consumption and DM [4]. SLI patients
tend to have multiple comorbidities, to be at high car-
diovascular risk, and untreated have up to 50% mortality
within 1 year of diagnosis [5]. Failure to promptly revas-
cularise in SLI patients is associated with greater use of
health care services and poorer outcomes including
major amputation and death [6].
SLI is currently managed by the following methods
[5, 6]:
1. Best medical therapy, comprising antiplatelet
medication, lipid modification, optimal diabetic/
blood pressure control, analgesia, and foot and
wound care
2. Surgical revascularisation, usually with autologous
vein bypass and/or endarterectomy
3. Endovascular revascularisation, performed under
local anaesthetic and with balloon catheters and/
or stents
4. Primary amputation, where the limb is considered
to be unsalvageable or the patient is either unwilling
or unable to undergo revascularisation
5. End of life care for those deemed unfit for
revascularisation or primary amputation
Endovascular revascularisation techniques are in-
creasingly being used as a first-line treatment for SLI,
especially when a suitable vein is not available for by-
pass. Traditionally, best endovascular treatment consists
of plain balloon angioplasty (PBA) with so-called ‘bail-out’
bare metal stenting (BMS) when PBA alone has been
technically unsuccessful. More recently, drug-coated
balloons (DCB) and drug-eluting stents (DES) have en-
tered the market. These devices are designed to deliver
various drugs (most commonly paclitaxel) locally to the
lesion with the aim of reducing the incidence of restenosis
following angioplasty or stenting [7, 8]. However, evidence
of clinical efficacy is lacking and there are unknown NHS
cost implications for their use when compared with PBA
and BMS. Consequently, the National Institute for Health
and Care Excellence (NICE) and the National Institute for
Health Research’s Health Technology Assessment (HTA)
programme both recommended that a randomised con-
trolled trial (RCT) be conducted in patients with SLI to
establish whether these new drug technologies confer add-
itional clinical benefit and represent a cost-effective use of
the available NHS resources [5, 9].
The BASIL-3 trial directly addresses the HTA call (13/81)
as a RCT in which patients with SLI secondary to athero-
sclerotic femoro-popliteal (FP) disease ± infrapopliteal (IP)
disease are randomly allocated to: PBA ± bail-out BMS,
DCB± bail-out BMS, or primary DES as their first revascu-
larisation strategy (see Figs. 1 and 2 for the BASIL-3
Consolidated Standards of Reporting Trials (CONSORT)
and Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) diagrams, respectively. A SPIRIT
Checklist is also provided as Additional file 1). BASIL-3
includes an internal pilot phase and health economic
analysis. The primary clinical outcome is amputation-free
survival (AFS) defined as the time to major (above the
ankle) amputation of the index limb or death from any
cause, whichever occurs first; secondary outcome measures
are shown in Table 1. The primary outcome for the cost-
effectiveness analysis is cost per quality-adjusted life year
(QALY) gained.
Methods
Indemnity
This is a clinician-initiated study. The sponsor (University
of Birmingham) holds public liability (negligent harm) and
clinical trial (negligent harm) insurance policies which
apply to this trial. Full details of indemnity arrangements
for this trial can be obtained from the sponsor.
Eligibility
Full inclusion/exclusion criteria are shown in Table 2.
All patients with SLI referred to vascular units within
participating NHS organisations may be considered for
enrolment (a full list of participating centres can be
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obtained from the trial sponsor). Participants should
have atherosclerotic FP disease and be judged by the
vascular multidisciplinary team (consisting of two endo-
vascular practitioners from either vascular surgery or
interventional radiology) to require early endovascular
revascularisation. Following diagnostic imaging, all par-
ticipants should be deemed suitable to receive any of the
three trial revascularisation strategies and should also
have adequate inflow to support these strategies (either
at the time of randomisation or achieved as part of a ‘hy-
brid’ procedure in which inflow is restored concurrently
with the FP revascularisation). Participants should have
an anticipated life expectancy of at least 6 months and
be able to complete the trial quality of life (QoL) and
resource use questionnaires. Patients will be excluded
from the trial if they lack capacity to provide written
informed consent, have received a previous intervention
to the target vessel within the past 12 months, or speak
insufficient English to guarantee informed consent
where translation services are not available.
Randomisation
Randomisation will be provided by a computer-generated
programme hosted online from Birmingham Clinical
Trials Unit (BCTU), using a minimisation algorithm with
a random element incorporated within it to ensure
balance between the three arms with regard to important
clinical variables. The following minimisation variables
will be used:
 Age (≤60, 61–70, 71–80, or >80 years)
 Sex (male or female)
 DM (presence or absence)
 CKD (presence or absence of stage 3 or higher)
 Severity of clinical disease (ischaemic rest pain
only, tissue loss only, or both)
 Artery being treated (superficial femoral, popliteal,
or both)
 Recruiting clinical centre
 Prior permissible intervention to the trial leg,
defined as an intervention to the target vessel more
Fig. 1 Flow diagram of study design
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than 12 months ago or to a different vessel in the
trial leg at any time (yes or no)
 Hybrid procedure planned (yes or no)
Randomisation will be performed between the three
endovascular interventions at a ratio of 1:1:1.
Baseline assessment
All participants will undergo a baseline assessment con-
sisting of:
1. Patient’s medical history including cardiovascular
risk factors, comorbidities, functional status as well
as prior vascular interventions and amputations
to both legs
2. Clinical status comprising peripheral pulses, ankle-
brachial pressure index (ABPI), toe-brachial pressure
index ((TBPI) where indicated), and current drug
therapy
3. Foot assessment using the ‘Wound, Ischaemia, and
Foot Infection’ (WiFi) and ‘Perfusion Extent Depth
Ischaemia Sensation’ (PEDIS) tools [10, 11]
4. Review of investigations including diagnostic imaging.
5. Assessment of patient’s QoL by use of the following
tools:
a. European quality of life 5 level score (EQ-5D-5L)
[12]
Fig. 2 Standard Protocol items: Recommendations for Interventional Trials (SPIRIT) diagram
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b. ICEpop CAPability measure for Older people
(ICECAP-O) [13]
c. Short form-12 health survey version 2 (SF-12)
[14]
d. Visual Analogue Scale pain score (VAS) [15]
e. Hospital Anxiety and Depression Scale (HADS) [16]
f. Vascular quality of life (VascuQoL) [17]
Trial intervention
The randomised trial intervention should normally take
place within 14 days of randomisation where clinically and
logistically practical. The randomised endovascular pro-
cedure will normally be carried out under local anaesthe-
sia with access via the common femoral artery. Technical
success of the procedure will be assessed by pulse status,
completion angiography, and haemodynamic measures
such as ABPI. Data collected relating to the randomised
procedure will include type and number of the devices
used by artery segment as well as disease severity. Stand-
ard data relating to the hospital admission or day case will
be collected and include summary of the admission, dis-
charge destination, additional interventions, and medical
complications.
Repeat and cross-over interventions
Further intervention is possible in all arms of the trial,
even when the trial endovascular intervention has been
successful (for example, due to multilevel disease or
following restenosis). This may either be with the same
endovascular intervention (re-intervention), one of the
alternative endovascular interventions (endovascular
cross-over intervention) or surgical intervention (sur-
gical cross-over intervention), each of which may be
repeated more than once.
Based on clinical experience, and data from the original
BASIL trial [18], we anticipate that further intervention:
 Will be required in up to 20% of participants
 Is most likely to be required within 12 months of
randomisation
Follow-up
Outcomes will be recorded at 1 month post interven-
tion and 6, 12, 24, and 36 months post randomisation.
Data collected will include peripheral pulses, ABPI,
TBPI (where indicated), functional status, and current
drug therapy. All participants will undergo a full re-
view of hospitalisations, further interventions (vascu-
lar, nonvascular, and amputations), and (serious)
adverse events (SAEs/AEs). The QoL assessments
(previously described) will be completed at each
follow-up time point as well as health resource usage
and personal circumstance assessments as part of the
economic analysis. A schedule of assessments for all
time points is given in Fig. 2.
Table 1 Secondary outcome measures
Overall survival
Major adverse limb events (MALE), defined as amputation (transtibial
or above) or any major vascular re-intervention (thrombectomy,
thrombolysis, PBA, stenting, or surgery)
In-hospital and 30-day morbidity and mortality
Major adverse cardiac events (MACE), defined as SLI and amputation
affecting the contralateral limb, ACS, or stroke
Relief of ischaemic pain (VAS, medication usage)
Psychological morbidity (using HADS)
Quality of life using generic (EQ-5D-5L, ICECAP-O, SF-12) and
disease-specific (VascuQoL) tools
Re- and cross-over intervention rates
Healing of tissue loss (ulcers, gangrene) as assessed by the PEDIS
and the WIFI scoring and classification systems
Extent and healing of minor (toe and forefoot) amputations
(also using PEDIS and WIFI)
Haemodynamic changes; absolute ankle and toe pressures, ABPI, TBPI
ABPI ankle-brachial pressure index, PBA plain balloon angioplasty, EQ-5D-5L
European quality of life 5 level score, HADS Hospital Anxiety and Depression
Scale, ICECAP-O ICEpop CAPability measure for Older people, PEDIS Perfusion
Extent Depth Ischaemia Sensation, SF-12 Short form-12 health survey version
2, TBPI toe-brachial pressure index, VAS Visual Analogue Scale, WIFI Wound,
Ischaemia, and Foot Infection tool
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Have SLI due to atherosclerotic FP, ± IP, PAD Have an anticipated life expectancy <6 months
Be judged by the responsible clinicians (consultant VS, IR) working as
part of a MDT to: Require early FP, ± IP, endovascular revascularisation
in addition to BMT, foot and wound care
Be, in the opinion of the clinician, unable to provide informed consent
Have or will have adequate ‘inflow’ to support all trial revascularisation
strategies
Be a non-English speaker where local translation facilities are insufficient
to guarantee informed consent
Judged suitable for all trial revascularisation strategies following
diagnostic imaging and a documented MDT discussion
Be judged unsuitable for the endovascular revascularisation strategies by
a vascular MDT
Able to complete QoL and resource use booklet Previous intervention (BET or bypass) to the target vessel within the
past 12 months
BET best endovascular therapy BMT best medical therapy IP infrapopliteal FP femoro-popliteal MDT multi-disciplinary team PAD peripheral arterial disease, QoL
quality of life SLI severe limb ischaemia
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Appropriate strategies to promote participant reten-
tion will be considered and implemented by the Trial
Management Group (TMG) as required.
Outcomes will be collected by research nurses at the
clinical centres on paper Case Report Forms (CRFs). All
data will be handled in accordance with the UK Data
Protection Act, 1998. CRFs, other than the Patient
Contact Form and Consent Form, will not bear the
participant’s name. For all other forms the participant’s
initials, date of birth and trial number will be used for
identification.
Safety reporting
The collection and reporting of AEs and SAEs will be in
accordance with Good Clinical Practice (GCP) and the
Research Governance Framework 2005. Safety will be
assessed continuously throughout the trial. There are no
investigational medicinal products being used as part of
BASIL-3 and all of the surgical procedures being tested
in this trial are part of current UK ‘standard of care’;
therefore, no (S)AEs are anticipated as a unique conse-
quence of participation in BASIL-3. In addition, at regu-
lar time points, the Trial Steering Committee (TSC) and
Data Monitoring Committee (DMC) will be provided
with details of all SAEs.
Sample size calculation
The sample size for this trial was calculated based on a
time-to-event analysis making two key comparisons be-
tween standard care and the new treatments (PBA ±
BMS versus DES; and PBA ± BMS versus DCB ± BMS).
To maintain an overall 5% type I error rate, each com-
parison will be tested at a significance level of 2.5% to
account for the increase in the risk of type I error associ-
ated with making two key comparisons. The total trial
duration is 5 years with 3 years’ recruitment (20% of
participants are to be recruited in year 1, and 40% in
years 2 and 3) and 2 years’ follow-up resulting in a mean
follow-up of 3.3 years per patient.
The sample size calculation is based on estimated
event rates in the PBA ± BMS arm taken from the angio-
plasty arm of the original BASIL trial (observed to be
0.70, 0.64, 0.52, 0.46, and 0.36 at the end of years 1–5,
respectively) [18]. The study is powered at 90% to detect
a hazard ratio of 0.60 for both comparisons reducing the
risk of the primary outcome (AFS). Across the three
arms, a total of 342 events would be required to detect a
hazard ratio of 0.60 (equivalent to an absolute difference
in AFS of 13% at year 2) at the 2.5% significance level.
Conservatively, allowing for 5% drop out for the primary
outcome (equivalent to 1% dropout in each year for
5 years) a total of 861 participants is required. It is antic-
ipated that around 50 UK clinical centres will be
required to achieve this recruitment target. Appropriate
strategies to meet recruitment targets will be discussed
and implemented by the TMG as required.
Pilot phase
Recruitment to BASIL-3 will be reviewed at the end of a
12-month pilot phase and discontinuation of the trial
will be considered if:
 Fewer than 15 clinical centres have been opened
 Fewer than two out of three opened centres have
recruited a participant
 Fewer than 100 participants have been randomised
 Fewer than 80% of participants have received their
allocated treatment
The completeness of the QoL measures will also be
evaluated at the end of the pilot phase. If completion rates
are poor, consideration will be given to discontinuing
some of these tools.
Data monitoring and interim analysis
After the first year of recruitment, we aim to assess re-
cruitment, retention, patient burden, and completeness
of data. A full efficacy and safety analysis report will be
reviewed by the DMC on an annual basis or more
frequently if required by the DMC or TMG. The DMC
will outline and agree the stopping rules for the trial
which will be documented in the DMC charter. It is
likely that the Haybittle-Peto boundary will be used. This
approach states that if an interim analysis of the primary
outcome shows, with a p value of less than 0.001, that
the treatments are different, then the trial should be
stopped early. This Haybittle-Peto approach will be used
as stopping guide, alongside data on important second-
ary endpoints and all other relevant evidence. A DMC
report and charter outlining the terms of reference
(including information on stopping rules) will be agreed
with the DMC. The report will specify which endpoints
are to be included in the reports to the TSC. The mem-
bership of the DMC is stated within the current trial
protocol which is published online [19].
Monitoring of BASIL-3 will ensure compliance with
GCP. A risk proportionate approach to the initiation,
management and monitoring of BASIL-3 will be adopted.
Clinical centres will permit trial-related monitoring,
audits, and Main Research Ethics Committee review;
providing direct access to source data/documents. Trial
participants will be informed of this during the informed
consent discussion and will consent to provide access to
their medical notes for these purposes. Important changes
to the trial conduct or trial protocol will be communicated
to all relevant interested parties and the trial sponsor
assumes responsibility for this.
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Final analysis
The final analysis for the BASIL-3 trial will occur once the
last randomised patient reaches the 24-month follow-up
assessment. Differences in the primary outcome (AFS) will
be assessed by comparing time from randomisation to
major limb amputation or death from any cause between
randomised groups, assessed up until the end of the
follow-up period which will be between 24 and 60 months.
The primary unadjusted analysis will use Kaplan-
Meier plots and test the difference between groups using
the log-rank test. Data will be censored when individuals
reach the end of follow-up or are lost to follow-up prior
to reaching the primary outcome. Further analysis of the
primary outcome will involve fitting flexible parametric
survival models to estimate both the relative and abso-
lute differences in the hazard of the primary outcome, to
model the underlying differences in hazard, and to allow
for nonproportional hazards. Addition of covariates to
this model will allow adjustment for any baseline differ-
ences, and the addition of their interactions with the
treatment allocation variable will test for subgroup ef-
fects. These models will allow examination of differences
in effect for short-, medium-, and longer-term follow-up.
The primary analysis of AFS will be undertaken on an
intention-to-treat basis according to allocated first inter-
vention, regardless of whether the intervention was de-
livered and whether repeat and cross-over interventions
were subsequently undertaken.
Secondary outcome measures that are based on a con-
tinuous scale will be analysed using a repeated measures,
multilevel model to examine any differential effect over
time. Where necessary, data transformations will be made
to fulfil modelling assumptions. Treatment effects from
the repeated measures model will be reported at the 1-
month, 12-month, and ‘end of follow-up’ time points.
Other outcome measures will be explored using standard
methods (Fisher’s Exact Test for dichotomous outcomes,
log-rank test for time to event data) and will also be re-
ported at 1 month, 12 months, and at the end of follow-up.
As the pattern of repeat and cross-over procedures is
likely to be multiple and complex, these will be measured
as outcomes and no attempt will be made to adjust for
them. Effect sizes will be presented as point estimates,
95% confidence intervals, and associated p values.
Sub-group analysis
Variation in the treatment effect between subgroups
will be limited to prespecified variables and investigated
using appropriate tests for interaction in survival and
repeated measures models. Variables likely to be con-
sidered will include, but will not necessarily be re-
stricted to, ischaemic rest/night pain only versus tissue
loss, or both rest pain and tissue loss, presence of DM,
and presence of CKD.
Economic analysis
The economic analysis will comprise both ‘within-study’
and ‘model-based’ analyses. The ‘within-study’ analysis
will be carried out to determine the cost-effectiveness of
all three trial-mandated interventions on the basis of the
patient-level data obtained during the study period.
Costs will take into account the use of NHS resources
related to the primary interventions and any secondary
procedures, readmissions, SAEs, hospital stays, day-case
admissions, outpatient visits, and appointments with
general practitioners and nurses. Changes in health-
related QoL and QALYs will be calculated according to
patients’ responses to the EQ-5D-5L instrument. Results
of the analysis will be presented in terms of cost per year
of AFS and cost per additional QALY gained. In line
with existing recommendations, the base-case analysis
will adopt a health care system (payer’s) perspective by
considering costs incurred by the NHS and Personal
Social Services [20].
The model-based analysis will be conducted to extend
the within-study evaluation by considering costs and
benefits likely to accrue beyond the study follow-up
period. This will be based on a decision analytic model
which will be built to serve as a framework for quantifying
long-term costs and outcomes.
Dissemination policy
The chief investigator will coordinate dissemination of
data from BASIL-3. All publications and presentations,
including abstracts, relating to the main trial will be
authorised by the BASIL-3 TMG. The results of the
analyses will be published in the name of the BASIL-3
Collaborative Group in peer-reviewed journals (provided
that this does not conflict with the journal’s policy). All
contributors to the trial will be listed, with their contri-
bution identified. Trial participants will be sent a sum-
mary of the final results of the trial which will contain a
reference to the full papers. All applications from groups
wanting to use BASIL-3 data to undertake original
analyses will be submitted to the TMG for consideration
before release. To safeguard the scientific integrity of
BASIL-3, trial data will not be presented in public before
the main results are published without the prior consent
of the TMG.
Discussion
BASIL-3 is a pragmatic RCT which is designed to in-
form future UK ‘standard of care’ for patients presenting
with SLI secondary to FP disease. Many of these patients
will have multilevel disease including both ‘inflow’
(aorto-iliac) disease as well as ‘outflow’ or ‘below the
knee’ (IP) disease. In such patients it will be permissible
to perform additional interventions in accordance with
routine practice at the same time as the randomised FP
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intervention. Moreover, it would also be permissible to
restore inflow by performing an aorto-iliac intervention
during an initial procedure and then randomise for an
endovascular FP intervention at a later date if this is still
deemed to be appropriate.
Enrolment into the BASIL-3 trial is on a per-patient
basis and only one leg may be randomised into the trial.
However, data from the original BASIL trial suggest that
up to a quarter of patients may present with bilateral
SLI, in which case the ‘worst’ leg (which is usually clinic-
ally obvious) should be entered as the trial limb.
Trial status
At the time of writing, the BASIL-3 trial was halfway
through the study’s pilot phase with 15 clinical centres
open to recruitment and over 50 participants randomised.
Additional file
Additional file 1: BASIL-3 SPIRIT Checklist. (DOC 122 kb)
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